Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2013)
Standards of Medical Care in Diabetes—2014Diabetes Care, 37
U. Schmidt-Erfurth, J. Garcia-Arumi, F. Bandello, K. Berg, U. Chakravarthy, B. Gerendas, J. Jonas, M. Larsen, R. Tadayoni, A. Loewenstein (2017)
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)Ophthalmologica, 237
Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care
J. Yau, S. Rogers, R. Kawasaki, E. Lamoureux, J. Kowalski, T. Bek, Shih-Jen Chen, J. Dekker, A. Fletcher, J. Grauslund, S. Haffner, R. Hamman, M. Ikram, T. Kayama, B. Klein, R. Klein, S. Krishnaiah, K. Mayurasakorn, J. O’Hare, T. Orchard, M. Porta, M. Rema, M. Roy, T. Sharma, J. Shaw, H. Taylor, J. Tielsch, R. Varma, Jie-Jin Wang, Ningli Wang, S. West, Liang Xu, Miho Yasuda, Xinzhi Zhang, P. Mitchell, T. Wong (2012)
Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 35
T. Sano, N. Hotta (2001)
[Diabetic retinopathy].Nihon rinsho. Japanese journal of clinical medicine, 59 Suppl 8
R. Simó, J. Sundstrom, D. Antonetti (2014)
Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic RetinopathyDiabetes Care, 37
D. Boyer, Y. Yoon, R. Belfort, F. Bandello, R. Maturi, A. Augustin, Xiao-Yan Li, Harry Cui, Y. Hashad, S. Whitcup (2014)
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.Ophthalmology, 121 10
J. Escobar-Barranco, Begoña Pina-Marín, Manel Fernández-Bonet (2015)
Dexamethasone Implants in Patients with Naïve or Refractory Diffuse Diabetic Macular EdemaOphthalmologica, 233
American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2019. Diabetes Care
(2019)
1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2019, 42
Effec - tiveness and safety of intravitreal dexamethasone implant ( Ozurdex ) in patients with diabetic macular edema : A real - world experience
Helen Andrew, G. Gossedge, J. Croft, N. Corrigan, Julia Brown, N. West, P. Quirke, D. Tolan, R. Cahill, D. Jayne (2016)
Summary of product characteristics
V. Castro-Navarro, E. Cervera-Taulet, C. Navarro-Palop, C. Monferrer-Adsuara, L. Hernández-Bel, J. Montero-Hernández (2019)
Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edemaBMC Ophthalmology, 19
A. Malclès, C. Dot, N. Voirin, A. Vie, É. Agard, D. Bellocq, P. Denis, L. Kodjikian (2017)
SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular HypertensionRetina, 37
Matias Iglicki, C. Busch, Dinah Zur, Mali Okada, Miriana Mariussi, J. Chhablani, Z. Cebeci, S. Fraser-Bell, V. Chaikitmongkol, A. Couturier, E. Giancipoli, M. Lupidi, P. Rodríguez-Valdés, M. Rehak, A. Fung, M. Goldstein, A. Loewenstein (2019)
DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX StudyRetina, 39
A. Malclès, C. Dot, N. Voirin, É. Agard, A. Vie, D. Bellocq, P. Denis, L. Kodjikian (2017)
REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT: The Reldex StudyRetina, 37
Objective: To gain information about multiple dexamethasone intravitreal implant (DEX-I) injections in diabetic macular edema (DME) eyes in real-life clinical settings. Methods: Patients with DME treated with multiple (≥5) DEX-I injections between January 1, 2014, and December 31, 2018, were retrospectively enrolled regardless of previous treatment with anti-VEGF agents. All patients were evaluated with best-corrected visual acuity (BCVA) in logMAR, ocular fundus, and spectral domain optical coherence tomography (SD-OCT) at baseline and at 3 months after the last DEX-I injection. Multiple DEX-I injections were administered when necessary in case of DME recurrence. Main efficacy measures were changes in BCVA and central retinal thickness (CRT) from baseline to 3 months after the last DEX-I injection; main secondary measures were an increase in intraocular pressure (IOP), the need for cataract surgery, endophthalmitis, and vitreous hemorrhage. Results: Seventeen patients (18 eyes) with DME and mean age (± SD) of 54.3 ± 8.16 years were treated with DEX-I injections between 2014 and 2018. The majority of eyes (77.8%) had been treated with a mean of 6.3 ± 3.2 anti-VEGF agents before switching to DEX-I. During a mean follow-up period of 37.6 months and after a mean number of 5.9 DEX-I injections, visual acuity improved or stabilized in 77.8% of all eyes, accompanied by a significant reduction in CRT. An increase in IOP was recorded in 38.8% of all patients, while a surgical procedure was needed for cataract in 73.3% of all phakic patients. Conclusions: In this real-life experience in Italy, multiple DEX-I treatments showed good efficacy with no new safety concerns. The follow-up duration of >3 years and a greater number of DEX-I intravitreal injections compared to other observations confirm the positive balance between risks and benefits of DEX-I in the long term.
Ophthalmologica – Karger
Published: Dec 1, 2020
Keywords: Diabetic macular edema; DME; Type 2 diabetes; Dexamethasone implant; DEX-I; Intravitreal treatment; Real-life experience
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.